RA CAPITAL MANAGEMENT, L.P. purchased $1.7M of COAG (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 67,669 indirectly-held shares of Hemab Therapeutics Holdings, Inc. (COAG) at an average of $24.97 ($24.89–$24.98, $1.69M total) across 2 trades over 2026-06-15 to 2026-06-16.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 17, 2026, 10:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COAG
Bullish
medium confidence
Mentioned
$COAG
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$COAGBullishLow
01

Why it matters

RA Capital Management reported open-market purchases with no 10b5-1 plan stated, increasing its indirect holdings to 6,444,637 shares.

02

Market read

This is a fresh ownership-change datapoint that may modestly support sentiment, but it does not introduce new operational or clinical information.

03

What to watch

Because the trades were executed days earlier (6/15–6/16) and there’s no accompanying company update, the market may already have priced in any sentiment effect.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-17; trades executed 2026-06-15 to 2026-06-16.

Background

The article is an SEC Form 4 insider/10% owner transaction disclosure for Hemab Therapeutics Holdings, Inc. (COAG).

Company-level read

Ticker impact

$COAGBullishMedium confidence
Context

RA Capital Management, a 10% owner, bought 67,669 Hemab Therapeutics shares in open-market trades totaling about $1.69M at ~$24.97.

Expected impact

Likely limited near-term impact; any effect would be sentiment/positioning rather than a re-rating catalyst.

Evidence & confidence

Form 4 shows size ($1.69M) and price range, but no new company-specific operating/regulatory/clinical information is disclosed.

Market effects

No sector-level read-through; this is a single-issuer ownership transaction.

None indicated.

None indicated.

Counterpoint

Large-holder buying on Form 4 can reflect portfolio rebalancing or indirect fund flows rather than a bullish thesis on near-term fundamentals.

Key entities

  • Hemab Therapeutics Holdings, Inc.

    COAG, the company whose shares were purchased; Form 4 reports the transaction details.

  • RA Capital Management, L.P.

    Reported open-market purchase of COAG shares totaling ~$1.69M across two trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A